JP2015505818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505818A5 JP2015505818A5 JP2014541396A JP2014541396A JP2015505818A5 JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5 JP 2014541396 A JP2014541396 A JP 2014541396A JP 2014541396 A JP2014541396 A JP 2014541396A JP 2015505818 A5 JP2015505818 A5 JP 2015505818A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- fgfr1
- therapeutic agent
- agent according
- ecd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124597 therapeutic agent Drugs 0.000 claims 37
- 239000012830 cancer therapeutic Substances 0.000 claims 35
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 32
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 29
- 101150016624 fgfr1 gene Proteins 0.000 claims 29
- 238000000034 method Methods 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 14
- 230000004544 DNA amplification Effects 0.000 claims 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 10
- 201000005202 lung cancer Diseases 0.000 claims 10
- 208000020816 lung neoplasm Diseases 0.000 claims 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000002230 centromere Anatomy 0.000 claims 8
- 210000000349 chromosome Anatomy 0.000 claims 8
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 230000002018 overexpression Effects 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 6
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 6
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims 6
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims 6
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 6
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims 6
- 102000048850 Neoplasm Genes Human genes 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- -1 FGFR3IIIc Proteins 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 238000000018 DNA microarray Methods 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 238000002105 Southern blotting Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000003595 spectral effect Effects 0.000 claims 2
- 230000004797 therapeutic response Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 3
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559259P | 2011-11-14 | 2011-11-14 | |
| US61/559,259 | 2011-11-14 | ||
| US201261616761P | 2012-03-28 | 2012-03-28 | |
| US61/616,761 | 2012-03-28 | ||
| PCT/US2012/064772 WO2013074492A1 (en) | 2011-11-14 | 2012-11-13 | Methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Division JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505818A JP2015505818A (ja) | 2015-02-26 |
| JP2015505818A5 true JP2015505818A5 (enExample) | 2017-01-05 |
Family
ID=48430074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541396A Pending JP2015505818A (ja) | 2011-11-14 | 2012-11-13 | 癌を治療する方法 |
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091502A Active JP6578318B2 (ja) | 2011-11-14 | 2017-05-02 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20130136740A1 (enExample) |
| EP (1) | EP2780033B1 (enExample) |
| JP (2) | JP2015505818A (enExample) |
| CN (2) | CN104168915A (enExample) |
| AU (1) | AU2012318247B2 (enExample) |
| CA (1) | CA2855818A1 (enExample) |
| HK (2) | HK1201462A1 (enExample) |
| TW (1) | TW201326201A (enExample) |
| WO (1) | WO2013074492A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA2732449A1 (en) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CA2855818A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression |
| TW201427681A (zh) | 2013-01-07 | 2014-07-16 | Superlab Far East Ltd | 用空間構象改變的重組干擾素治療腫瘤的方法 |
| MX2015015115A (es) * | 2013-05-01 | 2016-06-07 | Five Prime Therapeutics Inc | Metodos de tratamiento de cancer. |
| EP3294321B1 (en) * | 2015-05-12 | 2024-07-31 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| CN107794293A (zh) * | 2016-08-31 | 2018-03-13 | 安诺优达基因科技(北京)有限公司 | 一种基因捕获试剂盒 |
| CN109609640A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院上海高等研究院 | Etv4的用途 |
| EP4012021A4 (en) * | 2019-08-05 | 2022-11-30 | Genex Health Co.,Ltd | METHOD FOR CULTIVATION OF PRIMARY CELLS OF SOLID TUMORS IN LUNG CANCER AND PRIMARY TUMOR CELLS OF PLEEURAL EFFORT IN LUNG CANCER AND SUPPORTING REAGENT |
| CN111735950B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和ca125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN111912987B (zh) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Fgf18和he4联合用作早期卵巢癌生物标志物以及试剂盒 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486462A (en) | 1984-11-23 | 1996-01-23 | The Regents Of The University Of California | Differentiative expression modules |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| GB9001466D0 (en) | 1990-01-23 | 1990-03-21 | Erba Carlo Spa | Extracellular form of the human fibroblast growth factor receptor |
| DE69033109T2 (de) | 1989-07-06 | 1999-11-18 | The Regents Of The University Of California, Oakland | Rezeptoren für fibroblasten-wachstumsfaktoren |
| US5750371A (en) | 1990-04-27 | 1998-05-12 | Takeda Chemical Industries Ltd | Water-soluble mutein of FGF receptor, DNA and production thereof |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| DE69133281T2 (de) | 1990-07-06 | 2004-05-06 | Gencell S.A. | Rezeptoren der wachstumsfaktoren aus fibroblasten |
| US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US6517872B1 (en) | 1995-06-12 | 2003-02-11 | Yeda Research And Development Co., Ltd. | FGFR3 as a marker for mesenchymal skeletal progenitor cells |
| US6323316B1 (en) | 1996-06-18 | 2001-11-27 | The United States Of America As Represented By The Secretary Of The Department Of And Human Services | Fibroblast growth factor receptor activating gene 1 and related compositions and methods |
| DE19802377A1 (de) | 1998-01-22 | 1999-08-19 | Max Planck Gesellschaft | Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs |
| WO2000046380A2 (en) | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| PL403488A1 (pl) | 2001-05-24 | 2013-07-08 | Zymogenetics, Inc. | Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina |
| WO2003038054A2 (en) | 2001-10-31 | 2003-05-08 | New York University | Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds |
| JP4510938B2 (ja) | 2002-07-15 | 2010-07-28 | イミュネックス・コーポレーション | 哺乳動物細胞により産生されるタンパク質のシアル酸付加を調節する方法および培地 |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
| CA2550245A1 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| WO2005113596A2 (en) | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
| EP1773305A2 (en) | 2004-05-25 | 2007-04-18 | Yale University Corporation | Method for treating skeletal disorders resulting from fgfr malfunction |
| ATE454455T1 (de) | 2005-01-27 | 2010-01-15 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| WO2007059574A1 (en) | 2005-11-23 | 2007-05-31 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| AR059432A1 (es) | 2006-02-10 | 2008-04-09 | Genentech Inc | Anticuerpos anti-fgf19 y metodos que usan estos |
| JP2009536834A (ja) | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| AR063975A1 (es) | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| US20100111873A1 (en) | 2007-02-20 | 2010-05-06 | Russell Stephen J | Treating cancer with viral nucleic acid |
| CA2680046A1 (en) | 2007-03-23 | 2008-10-02 | The Translational Genomics Research Institute | Methods of diagnosing, classifying and treating endometrial cancer and precancer |
| WO2008133873A2 (en) | 2007-04-25 | 2008-11-06 | Aveo Pharmaceuticals, Inc. | Fgf-binding fusion proteins |
| UY31478A1 (es) | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
| MX342553B (es) | 2008-04-29 | 2016-10-04 | Novartis Ag | Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos. |
| CA2732449A1 (en) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| AU2010319327B2 (en) | 2009-11-13 | 2015-08-13 | Five Prime Therapeutics, Inc. | Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 |
| US8685931B2 (en) | 2009-12-17 | 2014-04-01 | Five Prime Therapeutics, Inc. | Hair growth methods using FGFR3 extracellular domains |
| WO2012068032A1 (en) | 2010-11-15 | 2012-05-24 | Five Prime Therapeutics, Inc. | Fgfr1 extracellular domain combination therapies |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| IT1404531B1 (it) | 2011-02-24 | 2013-11-22 | Sisvel Technology Srl | Procedimento e sistema di localizzazione indoor per terminali mobili in una rete di telecomunicazione mobile cellulare e relativo terminale mobile. |
| PH12013501878A1 (en) | 2011-03-17 | 2013-10-14 | Novartis Ag | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects |
| WO2012177481A2 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| CA2855818A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression |
| MX2015015115A (es) | 2013-05-01 | 2016-06-07 | Five Prime Therapeutics Inc | Metodos de tratamiento de cancer. |
-
2012
- 2012-11-13 CA CA2855818A patent/CA2855818A1/en not_active Abandoned
- 2012-11-13 TW TW101142331A patent/TW201326201A/zh unknown
- 2012-11-13 WO PCT/US2012/064772 patent/WO2013074492A1/en not_active Ceased
- 2012-11-13 US US13/675,255 patent/US20130136740A1/en not_active Abandoned
- 2012-11-13 US US14/357,336 patent/US10016484B2/en active Active
- 2012-11-13 CN CN201280066268.4A patent/CN104168915A/zh active Pending
- 2012-11-13 JP JP2014541396A patent/JP2015505818A/ja active Pending
- 2012-11-13 AU AU2012318247A patent/AU2012318247B2/en active Active
- 2012-11-13 HK HK15102035.6A patent/HK1201462A1/xx unknown
- 2012-11-13 CN CN201711171931.8A patent/CN107823630A/zh active Pending
- 2012-11-13 EP EP12849489.5A patent/EP2780033B1/en active Active
- 2012-11-13 HK HK15102726.0A patent/HK1202240A1/xx unknown
-
2017
- 2017-05-02 JP JP2017091502A patent/JP6578318B2/ja active Active
-
2018
- 2018-06-08 US US16/003,590 patent/US10537611B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505818A5 (enExample) | ||
| Tan et al. | PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA | |
| Yau | Precision treatment in colorectal cancer: Now and the future | |
| Wang et al. | Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers | |
| Shah et al. | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer | |
| Kim et al. | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma | |
| Bamias et al. | A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer | |
| Pietrantonio et al. | A review on biomarkers for prediction of treatment outcome in gastric cancer | |
| Shaib et al. | Markers of resistance to anti-EGFR therapy in colorectal cancer | |
| ES2661238T3 (es) | Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer | |
| Knapp et al. | Recently targeted kinases and their inhibitors—the path to clinical trials | |
| Kim et al. | Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| Guo et al. | L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival | |
| Young et al. | Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition | |
| Yu et al. | VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer | |
| Capdevila et al. | Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets | |
| JP2016526016A5 (enExample) | ||
| Chiang et al. | Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas | |
| Fang et al. | The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells | |
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| Kim et al. | Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma | |
| Lee et al. | Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy | |
| Choi et al. | Mutational and expressional analysis of ERBB 3 gene in common solid cancers |